VIII. The Industry
The broader beagle trade — from breeding facility to laboratory. Who breeds them, who buys them, what happens to them.
The Pipeline
Ridglan Farms is not an anomaly. It is part of a specialized industry that breeds beagles — tens of thousands of them, every year — for the sole purpose of selling them to laboratories where they will be tested on and, in nearly all cases, killed.
The supply chain is simple and brutal:
Born at a USDA Class A breeding facility (Marshall BioResources, Ridglan, or one of a handful of others) → Shipped at 4-6 months old to a contract research organization or pharmaceutical lab → Tested for weeks, months, or years — force-fed chemicals, forced to inhale compounds, injected with experimental drugs, surgically implanted with monitoring devices → Killed and dissected at the study's end.
An estimated 95%+ of research beagles are euthanized.
Why Beagles
Beagles became the standard laboratory dog not because they are the most biologically relevant species, but because of a convergence of practical and historical factors:
- **Temperament**: They are docile. They do not bite handlers. They tolerate restraint.
- **Size**: 8-14 kg. Small enough for cheap housing, large enough for repeated blood draws and surgical implants.
- **Cardiovascular similarity**: Their hearts model human cardiac responses — critical for drug safety testing.
- **Regulatory inertia**: Decades of beagle data create a baseline that regulators accept. Switching species is risky.
- **Pack mentality**: They tolerate group housing, reducing facility costs.
The result is that beagles account for the overwhelming majority of the 60,000-70,000 dogs used in US research annually.
The Breeders
There are fewer than a dozen major USDA Class A dog breeding facilities in the United States. The industry is dominated by:
Marshall BioResources (North Rose, NY) — the world's largest. Operating since the 1960s with facilities in at least 7 countries. "Marshall Beagle" is practically a brand name in the research community. Study protocols specify their dogs by name.
Ridglan Farms (Blue Mounds, WI) — the nation's second-largest. ~3,200 dogs, 16 employees. Now surrendering its license by July 2026 after 311 DATCP violations and a special prosecutor investigation.
Envigo (Cumberland, VA) — was a major breeder until the DOJ shut it down in 2022 after systematic AWA violations. ~4,000 beagles rescued. Owned by Inotiv Inc.
The Buyers
Contract Research Organizations (CROs) — companies that conduct testing on behalf of pharmaceutical firms — are the primary customers:
- **Charles River Laboratories**: ~$4 billion revenue. Also breeds its own research animals.
- **Labcorp Drug Development** (formerly Covance): Major preclinical testing operation.
- **Inotiv**: Acquired Envigo, then lost it. Stock price crashed.
Nearly every major pharmaceutical company uses beagles through these CROs: Pfizer, Merck, J&J, AstraZeneca, Novartis, Roche, Eli Lilly, BMS, AbbVie, GSK.
Purpose-Bred
"Purpose-bred" is the industry's term for what these dogs are. They are born into numbered cages, identified by ear tattoo, and raised without names, without outdoor access, without the experience of being a pet. At breeding facilities, they may undergo devocalization to reduce noise. Their feet are damaged by wire mesh flooring. They develop stereotypic behaviors — spinning endlessly — from the psychological trauma of confinement.
When they are shipped to labs, they are subjected to tests that may last months. At the end, they are killed.
The small percentage that are adopted out under "beagle freedom" laws often exhibit profound fear of everyday stimuli — grass, stairs, sunlight, human touch — because they have never experienced any of them.
The Money
A single research beagle costs $3,000-$7,000+. A chronic toxicology study using beagles can cost $1-5 million. The global preclinical CRO market exceeds $20 billion annually.
Reform
The FDA Modernization Act 2.0 (December 2022) removed the legal mandate for animal testing before human drug trials. The EPA committed to eliminating mammalian pesticide testing by 2035. Alternative methods — organ-on-a-chip, computational modeling, human organoids — are advancing.
But beagle testing is expected to continue for at least another decade, particularly for cardiovascular safety testing where no alternative has yet been validated to regulatory satisfaction.
Ridglan's closure is one facility. The industry continues.